Drug intelligence / Profile preview

xiaoer foshao hezhong

Development stage: Unknown
Lead developer: Jiangsu Kanion Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Xiaoer Foshao Hezhong is a Traditional Chinese Medicine (TCM) granule formulation developed by Jiangsu Kanion Pharmaceutical for the treatment of functional abdominal pain in children. The drug is designed to harmonize the spleen and stomach and alleviate pain by regulating gastrointestinal motility and reducing visceral hypersensitivity. It primarily targets the pediatric population where functional gastrointestinal disorders are common. The formulation likely incorporates botanical extracts such as Radix Paeoniae Alba (White Peony Root), which contains active compounds like paeoniflorin known for antispasmodic and analgesic properties. It is currently in Phase III clinical development in China.

Brand names: Xiaoer Foshao Hezhong Granules
Other names: Xiaoer Fushao Hezhong Keli小儿腹芍和中颗粒xiaoer fushao hezhong

Beyond the preview

Go deeper on xiaoer foshao hezhong.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xiaoer foshao hezhong.

Explore the full profile